XML 33 R22.htm IDEA: XBRL DOCUMENT v3.23.1
Stockholders' Equity
3 Months Ended
Mar. 31, 2023
Stockholders' Equity  
Stockholders' Equity

Note 15. Stockholders' Equity

Share Buyback Program

Pursuant to the Company’s existing share buyback program, the Company purchased 263,131 and 51,168 shares of its common stock during the three months ended March 31, 2023 and 2022, totaling $8.0 million and $1.2 million, respectively.

In November 2022, the Company’s Board of Directors authorized a $50.0 million increase to the Company’s share buyback program, which is expected to continue for an indefinite period of time. Since the inception of the program, the Company’s Board of Directors have authorized a total of $235.0 million in the share buyback program. The primary goal of the program is to offset dilution created by the Company’s equity compensation programs.

Purchases are made through open market and private block transactions pursuant to Rule 10b5-1 plans, privately negotiated transactions or other means as determined by the Company’s management and in accordance with the requirements of the SEC and applicable laws. The timing and actual number of treasury share purchases will depend on a variety of factors including price, corporate and regulatory requirements, and other conditions. These treasury share purchases are accounted for under the cost method and are included as a component of treasury stock in the Company’s condensed consolidated balance sheets.

Amended and Restated 2015 Equity Incentive Plan

As of March 31, 2023, the Company reserved an aggregate of 6,833,188 shares of common stock for future issuance under the Amended and Restated 2015 Equity Incentive Plan, or the 2015 Plan, including 1,202,802 shares, which were reserved in January 2023 pursuant to the evergreen provision in the 2015 Plan.

2014 Employee Stock Purchase Plan

As of March 31, 2023, the Company has issued 1,089,545 shares of common stock under the ESPP and 910,455 shares of its common stock remain available for issuance under the ESPP.

For the three months ended March 31, 2023 and 2022, the Company recorded ESPP expense of $0.3 million and $0.2 million, respectively.

Share-Based Award Activity and Balances

The Company accounts for share-based compensation payments in accordance with ASC 718, which requires measurement and recognition of compensation expense at fair value for all share-based payment awards made to employees and directors. Under these standards, the fair value of option awards and the option components of the ESPP awards are estimated at the grant date using the Black-Scholes option-pricing model. The fair value of RSUs is estimated at the grant date using the Company’s common share price. Compensation cost for all share-based payments granted with service-based graded vesting schedules is recognized using the straight-line method over the requisite service period.

The weighted-averages for key assumptions used in determining the fair value of options granted during the three months ended March 31, 2023 and 2022, are as follows:

Three Months Ended

March 31, 

    

2023

    

2022

    

Average volatility

 

41.5

%  

41.1

%  

Average risk-free interest rate

 

4.2

%  

2.2

%  

Weighted-average expected life in years

 

6.3

6.3

Dividend yield rate

 

%  

%  

A summary of option activity under all plans for the three months ended March 31, 2023, is presented below:

Weighted-Average

 

Weighted-Average

Remaining

Aggregate

 

Exercise

Contractual

Intrinsic

 

Options

Price

Term (Years)

Value(1)

 

(in thousands)

 

Outstanding as of December 31, 2022

7,929,150

$

17.66

    

    

    

    

Options granted

700,601

35.13

Options exercised

(102,024)

13.61

Options forfeited

(1,601)

31.21

Options expired

Outstanding as of March 31, 2023

8,526,126

$

19.15

5.15

156,491

Exercisable as of March 31, 2023

6,376,523

$

16.25

3.94

135,510

Vested and expected to vest as of March 31, 2023

8,270,035

$

18.83

5.03

154,400

(1)The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying awards and the estimated fair value of the Company’s stock for those awards that have an exercise price below the estimated fair value at March 31, 2023.

For the three months ended March 31, 2023 and 2022, the Company recorded expense of $3.0 million and $2.5 million, respectively, related to stock options granted under all plans.

Information relating to option grants and exercises is as follows:

Three Months Ended

 

March 31, 

    

2023

    

2022

 

(in thousands, except per share data)

 

Weighted-average grant date fair value per option share

$

16.67

$

15.06

Intrinsic value of options exercised

 

2,341

 

12,200

Cash received from options exercised

 

1,388

 

12,450

Total fair value of the options vested during the period

 

7,584

 

6,987

A summary of the status of the Company’s non-vested options as of March 31, 2023, and changes during the three months ended March 31, 2023, are presented below:

    

    

Weighted-Average

 

Grant Date

 

Options

Fair Value

 

Non-vested as of December 31, 2022

2,378,453

$

9.48

Options granted

 

700,601

16.67

Options vested

 

(927,850)

8.17

Options forfeited

 

(1,601)

13.96

Non-vested as of March 31, 2023

 

2,149,603

 

12.39

As of March 31, 2023, there was $21.4 million of total unrecognized compensation cost, net of forfeitures, related to non-vested stock option based compensation arrangements granted under all plans. The cost is expected to be recognized over a weighted-average period of 3.1 years and will be adjusted for future changes in estimated forfeitures.

Restricted Stock Units

The Company grants restricted stock units, or RSUs, to certain employees and members of the Board of Directors with a vesting period of up to five years. The grantee receives one share of common stock at a specified future date for each

RSU awarded. The RSUs may not be sold or otherwise transferred until vested. The RSUs do not have any voting or dividend rights prior to the issuance of certificates of the underlying common stock. The share-based expense associated with these grants was based on the Company’s common stock fair value at the time of grant and is amortized over the requisite service period, which generally is the vesting period using the straight-line method. For the three months ended March 31, 2023 and 2022, the Company recorded expenses of $2.9 million and $2.4 million, respectively, related to RSU awards granted under all plans.

As of March 31, 2023, there was $22.6 million of total unrecognized compensation cost, net of forfeitures, related to non-vested RSU based compensation arrangements granted under all plans. The cost is expected to be recognized over a weighted-average period of 3.1 years and will be adjusted for future changes in estimated forfeitures.

Information relating to RSU grants and deliveries is as follows:

Total Fair Market

 

Total RSUs

Value of RSUs

 

    

Issued

    

Issued(1)

 

(in thousands)

 

RSUs outstanding at December 31, 2022

 

1,007,052

RSUs granted

 

332,247

$

11,672

RSUs forfeited

 

(705)

RSUs vested(2)

 

(389,250)

RSUs outstanding at March 31, 2023

 

949,344

(1)The total fair market value is derived from the number of RSUs granted times the current stock price on the date of grant.
(2)Of the vested RSUs, 160,974 shares of common stock were surrendered to fulfil tax withholding obligations.

Share-based Compensation Expense

The Company recorded share-based compensation expense, which is included in the Company’s condensed consolidated statement of operations as follows:

Three Months Ended

March 31, 

2023

2022

(in thousands)

Cost of revenues

    

$

1,706

    

$

1,385

Operating expenses:

Selling, distribution, and marketing

 

209

 

168

General and administrative

 

3,357

 

2,861

Research and development

 

839

 

608

Total share-based compensation

$

6,111

$

5,022